Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) are increasingly used as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) harboring no actionable mutations; however, data on their efficacy among patients presenting with intracranial lesions are limited. This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhe, Wu, Fang, Xu, Qinqin, Song, Lianxi, Zhang, Xiangyu, Wang, Zhan, Deng, Li, Zhang, Yongchang, Zeng, Liang, Yang, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278740/
https://www.ncbi.nlm.nih.gov/pubmed/37195128
http://dx.doi.org/10.1097/CM9.0000000000002720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278740/
https://www.ncbi.nlm.nih.gov/pubmed/37195128
http://dx.doi.org/10.1097/CM9.0000000000002720

Ejemplares similares